SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:
BTIG Virtual Biotechnology Conference
Date: Monday, August 7th at 2:00pm E.T.
Format: Virtual Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran
Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 8, 2023 in New York, NY
Format: 1x1 Investor Meetings
Canaccord Genuity Annual Growth Conference
Date: Thursday, August 10, 2023 at 1:00pm E.T. in Boston, MA
Format: Fireside Chat and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran
Interested parties can access the live webcasts for these conferences (if available) from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replays will be available after the conclusion of the respective presentations.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani is progressing two RaniPill® capsules, the RaniPill®GO and the RaniPill®HC. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.07 |
| Daily Change: | -0.14 -6.14 |
| Daily Volume: | 36,483,463 |
| Market Cap: | US$98.910M |
October 30, 2025 October 23, 2025 October 23, 2025 October 17, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
